The Voice For Myotonic Dystrophy Patients in Europe

The Federation of European Myotonic Dystrophy Associations provides specialist support for people with Myotonic Dystrophy types I and II. Get in touch with our team of specialists for more information about our services.

What is Euro-DyMA ?

Euro-DyMA (European Dystrophia Myotonica Association) is a non-profit European patient association, entirely dedicated to Myotonic Dystrophy Type 1 (Steinert disease) and Type 2 (PROMM disease).

Ressources

Funding and sponsors policy (extract from Euro-DyMA statutes)

The Association pursues its objectives exclusively and directly in the public interest in accordance with the regulations on tax-deductible objectives of the French fiscal laws.

Funds for the realization of the Association’s tasks are exclusively received through:

  • Members fees.
  • Earnings from the Association’s assets.
  • Donations of money or in kind.
  • Subsidie.
  • Sponsorship by national or international organizations, after validation of the Board.
  • Fundraising. No public fundraising is allowed interfering with national collects.
  • Contracts with pharmaceutical/biotech industry according to specifications and requirements documents approved by the Board. No other funding contribution of any kind is accepted from pharmaceutical/ biotech industry.

Funding sources (2025)

List of all funding sources (industry and non-industry)

Annual memberships1100 €
Interests 2025 of saving account1268 €
MDF contribution to pharma day (*)15001 €
SIMPATHIC program (European Commission)1516 €
Industry sponsorship (pharma)0
Industry sponsorship (all except pharma)0
Grants/Donations (pharma)forbidden
Grant/Donations (all except pharma)0
Honorarium covering meetings with pharma and other organizations0

Revenues (2025)

  • Membership fees
  • MDF contribution to pharma day
  • SIMPATHIC program (European Commission)
  • Interest of saving account

(*) Euro-DyMA and Myotonic Dystrophy Foundation organize jointly an annual even called pharma day where all pharma involved in DM are allocated to present their activity to the scientific, clinicians and patient community. The applicable fee is the same for all pharma wishing to participate, decided in General Assembly and collected by one of the 2 federations according to the location of the event.

After deduction of organizing costs, the resulting balance is shared equally between both organizations. In 2025, the event was located in Indianapolis (U.S.A.). Consequently, the result appears as an MDF contribution and, the pharma contribution to our budget is set to 0. The ratio between pharma incomes and other incomes is also 0 in 2025.

The list of participating pharma in 2025 is:

  • Modalis Therapeutics,
  • Sanofi,
  • Vertex pharmaceuticals,
  • Arrakis,
  • Avidity biosciences,
  • Dyne Therapeutics,
  • PepGen,
  • Lupin neurosciences,
  • Arthex Biotech.

Each pharma paid a 5000US$ fee to present.

Code of conduct. Corporate Relations Guiding Principles 

Euro-DyMA accepts corporate support so long as it is in accordance with the following principles: compatibility with our statutes, transparency and independence.

Euro-DyMA will never engage in a corporate relationship that will affect the organization’s credibility or integrity.

Euro-DyMA will determine appropriate areas for corporate sponsorship, the types of sponsorship and the length or duration of sponsorship. All corporate relationships must have a Euro-DyMA related benefit to Euro-DyMA mission and its constituents.

Euro-DyMA will treat all corporate sponsors fairly and honestly. No sponsor is entitled to have any personal or professional relationship with the Euro-DyMA board members.

Euro-DyMA will exercise independent judgment in all its decision making. Thus, Euro-DyMA will retain sole discretion for the content, quality, scientific integrity of all sponsored programs, events and publications.

Euro-DyMA will communicate its policies regarding relationships with corporate sponsors.

Euro-DyMA will not endorse any product for financial gain and/or as part of any corporate relationship.

Euro-DyMA will have a written agreement with all corporate sponsors prior to the implementation of the corporate relationship.

Euro-DyMA will disclose financial and other benefits it receives from a corporate relationship upon receipt of a legitimate request.

Euro-DyMA retains the sole discretion to determine the use of its name, logo and identifying marks. Any use of the Euro-DyMA name, logo, and identifying marks in any corporation materials must be approved by Euro-DyMA in writing in advance of the use.

Our Members

AFM-Téléthon (France)
AFM-Téléthon (France)
Alain Geille (AFM-Téléthon, France)

Alain Geille
President of Euro-DyMA

Engineer, father and husband of DM patients

Head of Myotonic Dystrophies patient group of AFM-Téléthon

AFM

ABMM (Belgique)
ABMM (Belgium)

Cathy Gibson

Nurse and midwife
Steinert group manager of ABMM
Mother and wife of DM patients

ABBM

FMM (Italy)
FMM (Italy)

Giovanni Meola

Neurologist, MD, PhD

Founder and President of FMM

FMM

SN (The Netherlands)
SN (Netherlands)

Bas Haasakker
Vice-President of Euro-DyMA

Electronic Engineer and Art Historian, father of three daughters (two have DM1)
Service Operations Manager EMEA at Stryker

Spierziekten.nl

CureDM (UK)
CureDM (UK)

Peter Ashley

Family member with Congenital DM1.

ED representative on the European Reference Network for Neuromuscular Diseases. Chair Lay Research Panel, Muscular Dystrophy UK.
Engineer, Quality Management Systems, Change Management, International Product Certification.

CureDM

MDA-Hellas (Greece)
MDA-Hellas (Greece)

Antigone Karras

CEO of MDA Hellas

For over 18 years in the Neuromuscular field, Responsible for the creation, communication, and implementation of the organisation’s vision, mission and overall direction

MDA Hellas

DGM (Germany)
DGM (Germany)

Cornelia Dressler

Pharmacist, Ph.D.

DM 2 patient

Speaker council member of German Diagnosis group

DGM

Muskelsvindfonden (Danemark)
Muskelsvindfonden (Denmark)

Kirsten Andreasen

Social and health assistant. Mother and wife of DM1 patient

Muskelsvindfonden

ASRIMM (Suisse)
ASRIMM (Switzerland)
Monika Kaempf (ASRIMM, Switzerland)

Monika Kaempf

Medical professional, MSc PH and
Director of ASRIMM

ASRIMM

ASOCIACION B.E.N.E. (Basque Country)
ASOCIACION B.E.N.E. (Spain)

Antonio Alvarez

B.E.N.E.

NORBS (Sebia)
NORBS (Serbia)

Stefan Zifkovicsz

NORBS

MDA (Cyprus)
MDA (Cyprus)

MDA Cyprus

Asociación DM1 España (ADM1ES)

Javier Baigorri

ADM1ES

Associaçao Portuguesa de Neuromusculares (APN)

Joaquim Brittes

APN

Muscular Dystrophy Ireland (M.D.I.)

Alan Breathnach

Scientific Advisory Board

The Euro-DyMA SAB is composed of indisputable European experts in the domain of Myotonic Dystrophies. The SAB advise Euro-DyMA in scientific matters, meet to discuss the latest developments in their countries, and validate information for consideration and publication.

Pr. Benedikt Schoser
Pr. Benedikt
Schoser

Neurologist

F. Baur Institut

Munchen
(Germany)

Pr. Baziel Van
Engelen

Neurologist

Radboud University

Nimegen
(Netherlands)

Pr. Darren
Monckton

Professor of Human Genetics

University of Glasgow

Glasgow (U.K.)

Dr. A. B.
Ekström

Child Neurologist

Pediatric
Rehabilitation Center

Gothenburg (Sweeden)

Pr. Giovanni
Meola

Neurologist

University of Milan

Milano
(Italy)

Dr George
Papadimas

Consultant Neurologist

University Hospital

Athens
(Greece)

Dr Guillaume
Bassez

Neurologist

Institute of Myology

Paris
(France)

Dr Denis
Furling

CNRS
Research Director

Institute of Myology

Paris (France)

Dr Stojan
Peric

Neurologist

University of Belgrade

Belgrad
(Serbia)

Dr. Hilde
Brackmann

Pediatric Neurologist

Radboud University

Nimegen
(Netherlands)

A colorful stack of spiral-bound notebooks neatly placed on a wooden desk. Ideal for educational themes.

Statutes, partnerships

Euro-DyMA is an association constituted in accordance with the French law of 1901 concerning non-profit organisations. You can download our statutes below:

woman in pink long sleeve dress sitting on white bed

Join the fight against myotonic dystrophy by filling out our contact form!

© 2024 Federation of European Myotonic Dystrophy Associations